Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04170101
Other study ID # 2019RCTdeepNMBTHP
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 1, 2021
Est. completion date June 30, 2022

Study information

Verified date March 2020
Source AZ Sint-Jan AV
Contact Jan Paul Mulier, MD PhD
Phone +3250452490
Email jan.mulier@azsintjan.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A clinical deep NMB might relax the anterior muscles of the upper leg better than a moderate/superficial block giving a better exposure for the surgeon with less muscle trauma by traction to expose the hip. a continuous deep NMB (group A) versus a non deep NMB (group B) having a moderate to superficial block imitating common practice today as control group. Primary objectives are surgical exposure and Secondary objectives are Muscle damage creatine kinase changes, C-reactive protein (CRP), first time leaving bed postoperative, post operative pain as measured by opioid use postoperative at 24h, with a control of max VAS score during first 24 hour, length of hospital stay (LOS), number of adverse events using the Dindo-Clavien surgical complication score, QoR15 measured at 24h on the ward.


Description:

In this study, CRP levels are choosen as it is measured standard in every total hip arthroplasty (THA) procedure. CK is a good biomarker for muscle trauma and therefore chosen as second marker. The study is blinded for the treating surgeon, who will be making the assessment for the surgical conditions. The attending anesthesiologist is not blinded as he has to measure NMB in both groups and give a rocuronium infusion to stay deep in the study group. The anesthesiologist and the nurses following the patient on the post anesthetic care unit (PACU) and the ward are different from the attending anesthesiologist and are blinded. They will not be informed by the attending anesthesiologist on randomization allocation. Randomization: Group A deep NMB group: • 0,6 mg/kg LBW Rocuronium is used to facilitate intubation, and followed by an infusion of 1 mg/kg LBW/h , further adapted to keep post tetanic count (PTC) < 3 without informing the surgeon of the depth (surgeon is blinded) Group B moderate to superficial NMB group: - 0,6 mg/kg LBW rocuronium is used to facilitate intubation, not followed by an infusion or extra bolus.train of four ( TOF) and PTC are measured at the beginning of surgery without informing the surgeon of the depth. (surgeon is blinded) 2 weeks before surgery at consultation of orthopedics and anesthesia: - Inclusion criteria, signing informed consent, CRP blood sample - 15 Quality of recovery questions (QoR15) filled in to have a pre op status Day before surgery: - Verification that study can be performed ( equipment, surgeon, anesthesiologist and investigators available) Morning of surgery - Control signing of informed consent is done and patient still willing to continue the study - Attending anesthesiologist ask the randomization allocation at the secretary anesthesia without informing surgeon, colleagues and nurses on PACU and ward. Anesthesia & surgery performed - CRF is filled in with time stamps, dosing of drugs and monitoring values - Surgeon is asked for a surgical exposure grading ( 1-5) after initial incision, at the critical moment of prosthesis insertion and before closure. - In order to measure the degree of muscle damage, one light photo is taken of the muscles before closing and archived for later anonymous scoring by an independent orthopedic surgeon doing also THA by DAA but not around that day in the OR (3 surgeons do frequently THA by DAA). - If an opioid is given before PACU admission dose and time are noted in the clinical registration file (CRF) PACU - VAS score is recorded on admission, every hour and before leaving PACU. - The total dose of opioids given during the PACU are noted in the CRF Ward - Max visual analog pain score (VAS) during first 24 hours on the ward is noted in the CRF. - The QoR15 is repeated at 24 hours post surgery - A CRP blood sample is taken 24 hours post surgery - The total dose of opioids given on the ward till discharge is noted in the CRF Home - 2 weeks after surgery a phone call is given to request healthy state - and hear of any adverse event or complication. - and repeat the QoR15 questionnaire by phone


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date June 30, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - • Hip arthroplasty by anterior approach using Minimally Invasive Surgery Exclusion Criteria: - • Revision arthroplasty. - Allergy or contra indications to use any of the drugs included in anesthesia. - Addiction to or chronic opioid use before surgery. - Major cardiovascular, pulmonary, liver or renal insufficiency before surgery requiring possible post-operative intensive care admission. - Contra indication for a general anesthesia with intubation and mechanical ventilation.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
deep NMB
0,6 mg/kg LBW Rocuronium is used to facilitate intubation, and followed by an infusion of 1 mg/kg LBW/h , further adapted to keep PTC < 3
moderate NMB
0,6 mg/kg LBW rocuronium is used to facilitate intubation, not followed by an infusion or extra bolus.

Locations

Country Name City State
Belgium Azsintjan Brugge

Sponsors (1)

Lead Sponsor Collaborator
AZ Sint-Jan AV

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary surgical exposure After the surgical procedure the surgeon will be asked to score the surgical conditions on an adapted five point Leiden scale (validated scale):
max = 5 and best; min = 1 and worst grade 5: optimal surgical conditions, perfect access to the hip joint and excellent visibility.
grade 4: good conditions: adequate surgical conditions to perform the surgery, but not optimal grade 3: just acceptable conditions, surgical procedure is jeopardized, but adequate surgical result is still obtained, eventually after additional intervention grade 2: poor conditions, exposure and handling hindered resulting in suboptimal surgical outcome requiring adaptation of procedure or interventions to improve condition.
grade 1: extremely poor conditions, the surgeon is unable to work because of the inability to get access to the hip joint because of inadequate muscle relaxation and request to improve conditions first before continuing.
from incision till end of surgery stop at day zero
Secondary muscle injury This is scored on an adapted five point scale post surgery on a light photo taken at end of surgery before closing, by an orthopedic surgeon not around during surgery.
max = 5 and best; min = 1 and worst
grade 1: muscle severely damaged with open cuts; grade 2: muscle damaged with free tears; grade 3: muscle superficial damaged and swollen; grade 4: muscle intact, but swollen or perfusion not optimal grade 5: muscle intact without swelling and normal perfused.
on photo after procedure stop at day zero
Secondary creatinine kinase (CK) creatinine kinase (CK) changes as a measure for muscle trauma, at 24 hours postoperative versus baseline 24 hours after surgery stop at day 1
Secondary C-reactive protein (CRP) C-reactive protein (CRP) changes as a measure for inflammation, at 24 hours postoperative versus baseline. 24 hours after surgery stop at day 1
Secondary leaving bed First time leaving bed postoperative within 24 hours postoperative stop at day 1
Secondary Length of stay Length of hospital stay (LOS) measured in days up to one week post surgery stop at day 7
Secondary postoperative complications Number of adverse events using the Dindo-Clavien surgical complication score up to two weeks postoperative stop at day 14
Secondary quality of recovery 15 Quality of recovery questions (QoR15) measured at 24h on the ward and at 2 weeks post operative max: 150: best; min: 0: worst each question is answered on a scale from 0 to 10. 2 weeks postoperative stop at day 14
See also
  Status Clinical Trial Phase
Completed NCT05988476 - Investıgatıon of The Effıciency of Pulsed Electromagnetıc Field Therapy and Stretching Exercises N/A
Active, not recruiting NCT05344183 - Immediate and Short-term Effects of Low-level Laser N/A
Completed NCT05367648 - Effects of Protein Hydrolysate Supplement on Systemic Muscle Function Markers Following Resistance Type Exercise in Male Subjects N/A
Not yet recruiting NCT05279196 - Biological Variables Associated With the Response to Intensive Training in Athletes N/A
Completed NCT05254470 - Real-World Experience of Patients Treated for Musculoskeletal Injuries With SAM in Routine Care
Completed NCT03676205 - Platelet-Rich Plasma in Acute Muscle Injuries Phase 2
Completed NCT05827484 - The Effect of Combined Use of Anti-fibrotic Agent With Platelet Rich Plasma on Skeletal Muscle Healing After Acute Injuries Phase 4
Completed NCT04177537 - Real-World Experience of Athletes Treated With SAM
Completed NCT01525667 - Safety and Efficacy of IM Injections of PLX-PAD for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty Phase 1/Phase 2
Completed NCT04535635 - Effects of ART® on Lower Limb Myofascial Pain and Function N/A
Completed NCT04874662 - Nicotinamide (NAM) and Pyridoxine (Vitamin B6) on Muscle Regeneration ("Satellite-01 Study"). N/A
Completed NCT04742244 - Lemon Verbena Extract Oxidative Stress and Muscle Damage N/A
Active, not recruiting NCT04483986 - Does Rectus Re-approximation Cause Adhesion After Cesarean Section? N/A
Recruiting NCT06205537 - Muscle Health and Recovery in Older Adults N/A
Recruiting NCT05216666 - The Role of Surgical Approach on Residual Limping After Total Hip Arthroplasty N/A
Completed NCT02077413 - Muscle Injury Prevention & Rehabilitation in Military Personnel N/A
Terminated NCT01751503 - Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer N/A
Withdrawn NCT01497678 - Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) Coordinating Center N/A
Completed NCT04586712 - Efficacy of a Controlled Short-term Trial of Cannabidiol (CBD) Ingestion on Reducing Symptomatic Response and Facilitating Recovery After Induced Muscle Injury Phase 2
Completed NCT04123782 - Focused Shockwave Treatment in the Recovery Process of Acute Muscle Injuries in Soccer Players N/A